636 related articles for article (PubMed ID: 26475621)
21. Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients.
Wong KK; Gascoyne DM; Brown PJ; Soilleux EJ; Snell C; Chen H; Lyne L; Lawrie CH; Gascoyne RD; Pedersen LM; Møller MB; Pulford K; Murphy D; Green TM; Banham AH
Leukemia; 2014 Feb; 28(2):362-72. PubMed ID: 23884370
[TBL] [Abstract][Full Text] [Related]
22. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone.
Wu PY; Zhang XD; Zhu J; Guo XY; Wang JF
Hum Pathol; 2014 Aug; 45(8):1664-73. PubMed ID: 24931464
[TBL] [Abstract][Full Text] [Related]
23. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
24. Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma.
Ji H; Niu X; Yin L; Wang Y; Huang L; Xuan Q; Li L; Zhang H; Li J; Yang Y; An W; Zhang Q
Cell Physiol Biochem; 2018; 45(3):951-961. PubMed ID: 29428948
[TBL] [Abstract][Full Text] [Related]
25. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of PD-1 and TIM-3 on CD3+ T cells from diffuse large B-cell lymphoma.
Zhang L; Du H; Xiao TW; Liu JZ; Liu GZ; Wang JX; Li GY; Wang LX
Biomed Pharmacother; 2015 Oct; 75():83-7. PubMed ID: 26463635
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
28. Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
Ok CY; Chen J; Xu-Monette ZY; Tzankov A; Manyam GC; Li L; Visco C; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Zhao X; Ponzoni M; Ferreri AJ; Bertoni F; Farnen JP; Møller MB; Piris MA; Winter JN; Medeiros LJ; Young KH
Clin Cancer Res; 2014 Oct; 20(19):5113-23. PubMed ID: 25124685
[TBL] [Abstract][Full Text] [Related]
29. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients.
Shi Q; Shen R; Wang CF; Fan X; Qian Y; Ou-Yang BS; Zhao Y; Leboeuf C; Janin A; Cheng S; Wang L; Zhao WL
Mediators Inflamm; 2017; 2017():7960907. PubMed ID: 29109622
[TBL] [Abstract][Full Text] [Related]
31. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
[TBL] [Abstract][Full Text] [Related]
32. High KIF2A expression predicts unfavorable prognosis in diffuse large B cell lymphoma.
Zhang Y; You X; Liu H; Xu M; Dang Q; Yang L; Huang J; Shi W
Ann Hematol; 2017 Sep; 96(9):1485-1491. PubMed ID: 28616658
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
[TBL] [Abstract][Full Text] [Related]
34. Development and blind clinical validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL.
Knudsen S; Hother C; Grønbæk K; Jensen T; Hansen A; Mazin W; Dahlgaard J; Møller MB; Ralfkiær E; Brown Pde N
PLoS One; 2015; 10(2):e0115538. PubMed ID: 25692889
[TBL] [Abstract][Full Text] [Related]
35. Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma.
Nobili S; Napoli C; Puccini B; Landini I; Perrone G; Brugia M; Benelli G; Doria M; Martelli M; Finolezzi E; Di Rocco A; Del Fava E; Rigacci L; Di Lollo S; Bosi A; Mini E
Leuk Lymphoma; 2014 Sep; 55(9):2071-8. PubMed ID: 24289107
[TBL] [Abstract][Full Text] [Related]
36. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
37. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
38. [Expression and clinical significance of Ki-67 in diffuse large B cell lymphoma].
Zhou Y; Zhao Y; Bo J; Li YF; Ma C; Shi YN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1162-6. PubMed ID: 24156426
[TBL] [Abstract][Full Text] [Related]
39. Circulating long non-coding RNAs HOTAIR, Linc-p21, GAS5 and XIST expression profiles in diffuse large B-cell lymphoma: association with R-CHOP responsiveness.
Senousy MA; El-Abd AM; Abdel-Malek RR; Rizk SM
Sci Rep; 2021 Jan; 11(1):2095. PubMed ID: 33483590
[TBL] [Abstract][Full Text] [Related]
40. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma.
Kristensen LS; Hansen JW; Kristensen SS; Tholstrup D; Harsløf LB; Pedersen OB; De Nully Brown P; Grønbæk K
Clin Epigenetics; 2016; 8(1):95. PubMed ID: 27610206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
